Health Care [ 3/12 ] | Biotechnology [ 26/73 ]
NASDAQ | Common Stock
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.
It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 30, 25 | -1.87 Decreased by -592.59% | -2.32 Increased by +19.54% |
| Jun 18, 25 | -2.00 Decreased by -566.67% | -2.65 Increased by +24.53% |
| Mar 12, 25 | -3.00 Decreased by -581.82% | -2.76 Decreased by -8.70% |
| Nov 13, 24 | -2.78 Decreased by -768.75% | -3.15 Increased by +11.75% |
| Aug 13, 24 | -0.27 Increased by +20.59% | -0.32 Increased by +15.62% |
| May 9, 24 | -0.30 Increased by +3.23% | -0.33 Increased by +9.09% |
| Mar 14, 24 | -0.44 Decreased by -76.00% | -0.38 Decreased by -15.79% |
| Nov 13, 23 | -0.32 Decreased by -28.00% | -0.35 Increased by +8.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -13.70 M Increased by +36.40% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -16.56 M Increased by +23.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.04 M Increased by +119.20% | -20.22 M Increased by +37.33% | Decreased by -1.94 K% Decreased by -426.47% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -20.31 M Increased by +12.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.55 M Increased by +11.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.66 M Decreased by -6.98% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -5.43 M Decreased by N/A% | -32.26 M Decreased by -97.57% | Increased by +594.33% Decreased by N/A% |
| Sep 30, 23 | 7.00 M Increased by +N/A% | -23.10 M Decreased by -37.79% | Decreased by -330.04% Decreased by N/A% |